See Detailed Description
A randomized, open-label, parallel-group pilot study, to assess the pharmacodynamic effect
on dihydrotestosterone regulated gene expression, longitudinally and in a dose dependent
manner, of 0.5mg or 3.5mg dutasteride administered orally once daily, for three months in
men with symptomatic benign prostatic hyperplasia or during the period between baseline and
radical prostatectomy in men with biopsy-proven, clinically localized prostate cancer.
Interventional
Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Relative change in PSA(Prostate-specific antigen)expression per cell at 3 months
GSK Clinical Trials, MD, PhD
Study Director
GlaxoSmithKline
Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)
104274
NCT00375765
April 2005
Name | Location |
---|